As a clinical research/science experts, I mainly focuse on othe clinical trial methodology and translational research, especially metabolic and oncology area. For regulatory science, I have had a diverse and in-depth experience with major health agents (FDA, EMA, PMDA ect) and special interests on the NAM(New Approach Methodology).
이력
- –Chief Medical Officer, Hanmi Pharmaceuticals, Seoul, Korea
- –Project Mangaer, Science and Technology Office, Swiss Embassy in Korea
- –Medical Director, Novartis Korea, Seoul, Korea
- -Assistant Professor, Department of Otorhinolaryngology, Yonsei Univ. Wonju, Korea
- -Assistant Professor, Department of Otorhinolaryngology, Kwandong Univ. Koyang, Korea
학력
- –Yonsei University College of Medicine (B.Sc.)
- –Ajou University College of Medicine (Msc. , PhD. can.)
논문
- –Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabets Caer, 2022.7
- –Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation, 2023.2
- –Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation 2021.11
